Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 12 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Prednisolone increases mortality in patients with severe alcoholic hepatitis

In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA, reports the latest issue of Gastroenterology.

News image

Infections are common in patients with severe alcoholic hepatitis, but little information is available on how to predict their development or their effects on patients. 

Prednisolone is advocated for treatment of severe alcoholic hepatitis, but can increase susceptibility to infection. 

Dr Stephen Atkinson and colleagues from the United Kingdom compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in severe alcoholic hepatitis.

The team analyzed data from 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the efficacy of treatment with prednisolone or pentoxifylline in patients with severe alcoholic hepatitis. 

There were 547 patients that received prednisalone.

10% of patients receiving prednisolone developed an infection after treatment
Gastroenterology
The team reported that 546 were treated with pentoxifylline. 

The trial was conducted from 2011 through 2014. 

Data on development of infection were collected at evaluations performed at screening, baseline, weekly during admission, on discharge, and after 90 days. 

Patients were diagnosed with infection based on published clinical and microbiologic criteria. 

Risk factors for development of infection and effects on 90-day mortality were evaluated separately in patients treated with prednisolone, and patients not treated with prednisolone using logistic regression. 

The research team measured pretreatment blood levels of bacterial DNA (bDNA) in 731 patients.

Of the 1092 patients in the study, 135 had an infection at baseline, 251 developed infections during treatment, and 89 patients developed an infection after treatment. 

The team found no association between pentoxifylline therapy, and the risk of serious infection, infection during treatment, or infection after treatment. 

Infections classified as serious were more frequent in patients treated with prednisolone. 

The research team found no association between prednisolone therapy and infection during treatment. 

The researchers found that 10% of patients receiving prednisolone developed an infection after treatment vs 6% of patients not given prednisolone. 

Development of infection was associated with increased 90-day mortality in patients with severe alcoholic hepatitis treated with prednisolone, independent of model for end-stage liver disease or Lille score. 

The team noted that high circulating bDNA predicted infection that developed within 7 days of prednisolone therapy, independent of Model for End-Stage Liver Disease and white blood cell count. 

In patients who did not receive prednisolone, the research team observed that infection was not independently associated with 90-day mortality or levels of bDNA.

Dr Atkinson's team concludes, "Patients with severe alcoholic hepatitis given prednisolone are at greater risk for developing serious infections and infections after treatment than patients not given prednisolone, which may offset its therapeutic benefit."

"Level of circulating bDNA before treatment could identify patients at high risk of infection if given prednisolone."

"These data could be used to select therapies for patients with severe alcoholic hepatitis."

Gastroenterol 2017: 152(5): 1068–1077.e4
05 April 2017

Go to top of page Email this page Email this page to a colleague

 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 01 December 2017 
Therapeutic drug monitoring in IBD
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 29 November 2017 
Medical cannabinoid legalization policy and vomiting
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 28 November 2017 
Surgical treatment delays and colon cancer survival
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us